Hospital-acquired pneumonia (HAP) and ventilator-associated pneumonia (VAP) are common hospital-acquired infections that are associated with mortality rates as high as 50%.

Ceftolozane/tazobactam (C/T), a combination of a potent antipseudomonal cephalosporin (ceftolozane) with a beta-lactamase inhibitor (tazobactam), is primarily renally excreted, and requires dose adjustment based on renal function.

C/T is approved in the European Union and United States for the treatment of adults with complicated urinary tract infections (cUTI; including pyelonephritis), complicated intra-abdominal infections (cIAI; to be used in combination with metronidazole in the United States), and HAP/VAP.

A C/T 3 g (ceftolozane 2 g/tazobactam 1 g) dose, or C/T dose adjusted based on renal function, administered as a 1-hour infusion every 8 hours was evaluated in patients with ventilated HAP or VAP in the phase 3, randomized, controlled, double-blind ASPECT-NP study.

The objective of this analysis was to apply probability of target attainment (PTA) analyses to data from the ASPECT-NP study to support the recommended C/T dosing regimen in patients with HAP/VAP.

Presented at: the 30th European Congress of Clinical Microbiology & Infectious Diseases (ECCMID); April 18-21 2020; Virtual.

By: Zhang Z, Yogesh T Patel, Gao W, Johnson MG, Jill Fiedler-Kelly, Bruno CJ, Rhee E, De Anda C, Feng HP.